A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension.
Phase of Trial: Phase II/III
Latest Information Update: 23 Feb 2012
At a glance
- Drugs Bosentan (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms BUILD-1
- Sponsors Actelion Pharmaceuticals
- 23 Feb 2012 Actual initiation date (Aug 2003) added as reported by ClinicalTrials.gov.
- 23 Feb 2012 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 23 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00071461).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History